头孢地尔MIC多中心性能评估:ComASP与CLSI微量肉汤稀释法比较
多中心研究评估ComASP头孢地尔药敏板与CLSI微量肉汤稀释法检测肠杆菌目、鲍曼不动杆菌和铜绿假单胞菌临床分离株及挑战株MIC的表现。ComASP读数(100%生长抑制终点)下重复性优秀,基本一致率和分类一致率普遍高于CLSI读数,且无极重大误差。
要点
- ComASP读数终点下鲍曼不动杆菌基本一致率达96.7%,明显高于CLSI读数的78.3%。
- ComASP读数下三类菌均无极重大误差,CLSI读数下铜绿假单胞菌和鲍曼不动杆菌出现极重大误差。
- ComASP头孢地尔板采用铁缺乏培养基,可减少铁水平对MIC结果的干扰。
核心结论
- 使用ComASP读数终点时,ComASP头孢地尔是检测相关临床分离株头孢地尔MIC的可靠方法。
研究设计与样本
- 多中心研究,肠杆菌目、鲍曼不动杆菌和铜绿假单胞菌临床分离株及挑战株分别由三个和一个中心检测,采用CLSI微量肉汤稀释法与ComASP并行MIC检测并做重复性和质控。
主要发现
- 重复性优秀,97.4%在模态MIC±1稀释度内;质控除一个中心两株大肠埃希菌ATCC 25922外均在CLSI质控范围内。
- 临床与挑战肠杆菌目基本一致率84.3%(CLSI读数)和95.7%(ComASP读数)。
- 铜绿假单胞菌基本一致率83.3%(CLSI读数)和93.7%(ComASP读数),鲍曼不动杆菌78.3%(CLSI读数)和96.7%(ComASP读数)。
- 分类一致率肠杆菌目两种读数均为92.4%,铜绿假单胞菌89.7%(CLSI读数)和92.1%(ComASP读数),鲍曼不动杆菌72.8%(CLSI读数)和91.3%(ComASP读数)。
- ComASP读数无极重大误差;CLSI读数下铜绿假单胞菌1例、鲍曼不动杆菌3例极重大误差。
关键数值与推荐
- ComASP读数定义为100%生长抑制的第一孔;CLSI读数定义为生长减少<1 mm或轻度浑浊/微弱浊度的第一孔。
- 重复性97.4%在模态MIC±1稀释度内。
- 基本一致率:肠杆菌目84.3%(CLSI读数)/95.7%(ComASP读数);铜绿假单胞菌83.3%/93.7%;鲍曼不动杆菌78.3%/96.7%。
- 分类一致率:肠杆菌目92.4%/92.4%;铜绿假单胞菌89.7%/92.1%;鲍曼不动杆菌72.8%/91.3%。
临床怎么用
- 临床微生物实验室检测头孢地尔MIC时可选用ComASP并采用ComASP读数终点以提高与CLSI微量肉汤稀释法的一致性。
- ComASP板为冻干多孔格式可室温保存,含铁缺乏阳离子调节MH肉汤,便于常规开展。
局限性
- 肠杆菌目、鲍曼不动杆菌和铜绿假单胞菌的检测中心数分别为三个和一个,各菌种评价中心数量不均衡。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: The performance of the Liofilchem Compact Antimicrobial Susceptibility Panel (ComASP) Cefiderocol was evaluated in a multicenter study. Enterobacterales, Acinetobacter baumannii, and Pseudomonas aeruginosa clinical isolates and challenge isolates were tested by three and one sites, respectively. Minimum inhibitory concentration (MIC) testing was performed by the Clinical and Laboratory Standards Institute (CLSI) broth microdilution and ComASP, which included two reading endpoints (CLSI read; MIC is the first well in which reduction of growth is <1 mm or light haze/faint turbidity] and ComASP [ComASP read; MIC is the first well at which 100% inhibition of growth occurs]). Each site performed reproducibility and quality control (QC) by ComASP and broth microdilution (BMD). Reproducibility was excellent (97.4% within ±1 dilution of modal MIC). All QC results were within CLSI QC ranges by BMD and ComASP, except for two E. coli ATCC 25922 results from one site. Essential agreement for combined clinical and challenge Enterobacterales was 84.3% (CLSI read) and 95.7% (ComASP read), P. aeruginosa was 83.3% (CLSI read) and 93.7% (ComASP read), and A. baumannii was 78.3% (CLSI read) and 96.7% (ComASP read). Categorical agreement for Enterobacterales was 92.4% for both CLSI read and ComASP read, for P. aeruginosa was 89.7% (CLSI read) and 92.1% (ComASP read), and for A. baumannii was 72.8% (CLSI read) and 91.3% (ComASP read). There were no very major errors using the ComASP read. One very major error for P. aeruginosa occurred using the CLSI read method. Three very major errors for A. baumannii occurred using the CLSI read method. ComASP Cefiderocol was shown to be a reliable method for testing cefiderocol MIC against relevant clinical isolates when ComASP read is used. IMPORTANCE: There are very limited commercial methods available to clinical laboratories for cefiderocol minimum inhibitory concentration (MIC) testing. The Compact Antimicrobial Susceptibility Panel (ComASP) Cefiderocol method includes iron-depleted cation-adjusted Mueller-Hinton broth, which eliminates variability in cefiderocol MIC results based on iron levels. The lyophilized multi-well format of ComASP also provides for room temperature storage. In comparison to what an individual lab may do for method verification, this multi-site, multi-isolate study provides a robust evaluation and greater assurance to clinical microbiologists of the method's accurate and reproducible performance.
引用
- Koeth LM, DiFranco-Fisher JM, Palavecino E, et al. A multicenter performance evaluation of cefiderocol MIC results: ComASP in comparison to CLSI broth microdilution. J Clin Microbiol. 2024. PMID: 39745470. doi:10.1128/jcm.00926-24
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。